New diabetes drug from Novo Nordisk saves lives - Good news, a new diabetes drug has been announced by the researchers. Its name is Victoza. It sold by Danish drug giant Novo Nordisk. It can prevent heart attacks, strokes, and cardiovascular deaths. (Read more: diabetes mellitus definition).
It is the other diabetes medicine ever to do so. The first drug is a Jardiance pill. It is sold by Eli Lilly LLY and Boehringer Ingelheim, presented its positive outcomes just last year. Hopefully, The method that doctors treat diabetes mellitus will be changed due to the new drug. Usually, the treatments doctors reach for after metformin, the tried-and-true first-line drug, which is generic.
Jhon Buse, the North Carolina University, Chapel Hill research leader whose the study was funded by Novo Nordisk - say that “There is a building momentum that we do require to rethink the method diabetes is cared for in America." Furthermore, he said, "I can ensure you that these trials would not have been finished if it had not been for the regulations of FDA." Nowadays, the ordinances for diabetes drugs from the Food and Drug Administration become tougher. It is because many drug industries had previously decried, saying it was keeping new medicines from the market and hurting patients. Then Buse says, “Before the guidance I was always pushing on companies to do these trials.” We hope both businesses and patients are getting benefit from the FDA's toughness regulations.
That fact goes against one of the common narratives in the drug company and among the FDA’s critics: that great management slow access of patient. In some cases, they also make a bar for industry to leap over, and deliver billions of dollars in impairs to companies that actually manage to cure patients, not just blood check results.
Novo Nordisk can now tell their patients and insurers that the alternative to its drug is an earlier death. Why? Because the study presented at the annual conference of the American Diabetes Association and published in the New England Journal of Medicine show good results. 9,340 patients were randomly assigned to get either Victoza or placebo for a median of 3.8 years. For those on Victoza, 13% got a heart attack, stroke, or death. It is compared to 14.9% on placebo, a 13% decrease in risk. Decrease in cardiovascular death (22%) and death from any cause (15%) was also statistically significant. A supposed side effect of the drug like pancreatitis did not show up at all. Besides that, patients on Victoza lost weight about 5 pounds (2.3 kilograms) more than the patients that use the placebo.
The outcomes are less puzzling than those for Lilly and Boehringer’s Jardiance, which seemed to have a benefit from its effect on blood pressure or some other mechanism. The benefit is not from reducing artery disease. That drug, though, had a very obvious impact on death.
Executive vice president of Novo Nordisk for research and development, Mads Krogsgaard Thomsen, says he believes the results will help Victoza, which works by imitating the glucagon-like peptide one (GLP-1), a substance of the body uses as the signal to control the blood sugar. Eli Lilly’s Trulicity and GlaxoSmithKline’s Tanzeum are other drugs in this class.
Semaglutide, a follow-up drug from Novo Nordisk, which needs to be given less often than Victoza, has already prevented heart attacks, stroke diseases, and deaths in a trial of 3,000 patient; full outcomes are coming.
0 Response to "New Diabetes Drug From Novo Nordisk Saves Lives"
Post a Comment